Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer

LIESA DZIGGEL, NIKLAS GEBAUER, TOBIAS BARTSCHT, STEVEN E. SCHILD and DIRK RADES
Anticancer Research April 2018, 38 (4) 2391-2394;
LIESA DZIGGEL
1Department of Radiation Oncology and Hematology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKLAS GEBAUER
2Department of Medical Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOBIAS BARTSCHT
2Department of Medical Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEVEN E. SCHILD
3Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIRK RADES
1Department of Radiation Oncology and Hematology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rades.dirk@gmx.net
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Patients with brain metastases from thyroid cancer are extremely rare. This study evaluated clinical factors for survival following whole-brain radiotherapy (WBRT) alone. Patients and Methods: In six patients, the following factors were analyzed for survival: Regimen of WBRT (5×4 Gy vs. 10×3 Gy), gender, age (≤55 vs. ≥56 years), Karnofsky performance score (KPS) (60% vs. 70-80%), number of brain lesions (2-3 vs. ≥4) and number of extra-cranial metastatic sites (one vs. more than one). Results: KPS 70-80% (p=0.036) and involvement of only one extra-cranial site (p=0.018) were associated with better survival on univariate analysis. On Cox regression analysis, KPS (p=0.14) and number of extra-cranial sites (p=0.14) showed trends for association with survival. In patients with KPS 70-80% and only one extra-cranial site, 6-month survival was 100%, no patient with KPS 60% and more than one extra-cranial site survived to 6 months. Conclusion: KPS and number of involved extra-cranial metastatic sites were associated with survival and may be helpful for individualizing therapy in patients with brain metastases from thyroid cancer.

  • Thyroid cancer
  • metastatic lesions to the brain
  • whole-brain radiotherapy alone
  • survival
  • predictive factors

Patients with brain metastases from thyroid cancer are extremely rare and represent fewer than 1% of all patients with metastasis from a solid tumor to the brain (1, 2). Therefore, only very little is known about this group of patients with cancer. The current study was conducted to add more data for patients with thyroid cancer who received whole-brain radiotherapy (WBRT) alone for intracerebral metastatic lesions. The main goal of this study was identification of clinical factors associated with survival. Such factors could be used to tailor treatment, in particular the radiotherapy regimen for an individual patient, taking into account the most appropriate overall treatment time.

It is generally agreed that when considering treatment effect and potential toxicities, patients with a poor survival prognosis should preferentially receive a shorter course of WBRT and those with a more favorable prognosis a longer course of WBRT (2-4). It has been shown that factors predicting survival can differ considerably between various solid tumor types which lead to brain metastases (5-13). Therefore, studies performed to identify the significant predictors separately for each tumor entity are important.

Patients and Methods

Six patients who received WBRT alone for more than one metastasis to the brain from thyroid cancer between 2000 and 2004 were included in this retrospective study and evaluated for survival. A total of six clinical factors were analyzed for a potential association with outcome following WBRT. The investigated factors included were the regimen of WBRT (5×4 Gy over 2 weeks vs. 10×3 Gy over 3 weeks), gender, age at the time of WBRT (≤55 vs. ≥56 years, median=55.5 years), the Karnofsky performance score (KPS of 60% vs. 70-80%, median=65%), the number of metastatic lesions to the brain (2-3 vs. ≥4, median=3) and the number of involved extra-cranial metastatic sites (one vs. more than one, median=1) (Table I). Initially, a univariate analysis of survival was performed using the Kaplan–Meier method supplemented with the log-rank test (14). Subsequently, those factors achieving significance on univariate analysis (p<0.05) were investigated in a multivariate fashion (Cox regression model).

Results

The median follow-up time was 8 months (range=1-18 months) for the entire cohort and 12.5 months (range=7-18 months) for the patients who were alive at their last follow-up. For the entire cohort, the survival rates at 6 and 12 months were 67% and 44%, respectively. On univariate analysis, a KPS of 70-80% (vs. 60%, p=0.036) and involvement of only one extra-cranial metastatic site (vs. more than on site, p=0.018) were significantly associated with survival (Table II). In the subsequent Cox regression analysis, both KPS (p=0.14) and number of extra-cranial metastatic sites (p=0.14) showed trends for associations with survival.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Distribution of the investigated clinical factors.

The importance of these two clinical factors is further supported by the finding that patients with a KPS of 70-80% and involvement of only one extra-cranial metastatic site achieved a 6-month survival rate of 100%, whereas those patients with a KPS of 60% and involvement of more than one extra-cranial metastatic site had a 6-month survival rate of 0%.

Discussion

Thyroid cancer is considered an important disease, and considerable research has been performed to improve the prognoses of these patients. Clinical studies have been reported on surgical techniques, novel systemic treatments and multidisciplinary approaches (15-17). Another field of research aims to identify prognostic factors that allow clinicians to better judge a patient's prognosis, which is important for designing individualizing therapy. Prognostic factors have already been identified for treatment of the primary tumor and also for metastatic disease (18-23). However, to our knowledge no study exists focusing on patients with thyroid cancer who require treatment for metastases to the brain. The most frequently used treatment modality for brain metastases is WBRT, either alone or combined with focal therapies such as neurosurgical resection and stereotactic radiosurgery (2). This study focused particularly on patients treated with WBRT alone.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Univariate analyses: survival rates at 6 and 12 months following WBRT.

In this study, two predictors of survival, namely the KPS and number of extra-cranial metastatic sites, were identified on univariate analyses. The prognostic value of the performance status for patients receiving treatment for brain metastases has been described for other tumors and was found to be prognostic for this cohort. The prognostic impact of the number of extra-cranial metastatic sites has been found prognostic in a few studies, mainly in patients with brain metastases from breast cancer or lung cancer (24-27).

Taking into account the retrospective design of the present study and the small number of patients evaluated, the results of the present study may serve to guide clinicians when they aim to tailor the radiation treatment to a patient with metastases to the brain from thyroid cancer. Since no patient with a KPS of only 60% and metastatic involvement of more than one extra-cranial site survived longer than 4 months, these patients appear good candidates for short-course WBRT with 5×4 Gy over 1 week, which has shown to be non-inferior to longer-course WBRT programs with 30-40 Gy over 2-4 weeks (3). In contrast, patients with the most favorable survival prognosis (KPS >60% and involvement of maximum one extra-cranial site) could benefit from longer-course WBRT programs with higher total doses in terms of better intracerebral control and survival (4). Patients of the latter group with a limited number of cerebral lesions may also be good candidates for focal therapies (2).

In conclusion, in this study, the KPS and the number of involved extra-cranial metastatic sites were identified to be associated with survival in patients receiving WBRT alone for brain metastases from thyroid cancer. Although this study was small, these two factors could be used for personalization of care for this patient group.

Footnotes

  • Conflicts of Interest

    On behalf of all Authors, the corresponding Author states that there is no conflict of interest related to this study.

  • Received January 15, 2018.
  • Revision received February 9, 2018.
  • Accepted February 13, 2018.
  • Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    : Cancer statistics, 2017. CA Cancer J Clin 67: 7-30, 2017.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Tsao MN,
    2. Rades D,
    3. Wirth A,
    4. Lo SS,
    5. Danielson BL,
    6. Gaspar LE,
    7. Sperduto PW,
    8. Vogelbaum MA,
    9. Radawski JD,
    10. Wang JZ,
    11. Gillin MT,
    12. Mohideen N,
    13. Hahn CA,
    14. Chang EL
    : Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2: 210-225, 2012.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rades D,
    2. Kieckebusch S,
    3. Lohynska R,
    4. Veninga T,
    5. Stalpers LJ,
    6. Dunst J,
    7. Schild SE
    : Reduction of overall treatment time in patients irradiated for more than three brain metastases. Int J Radiat Oncol Biol Phys 69: 1509-1513, 2007.
    OpenUrlPubMed
  4. ↵
    1. Rades D,
    2. Panzner A,
    3. Dziggel L,
    4. Haatanen T,
    5. Lohynska R,
    6. Schild SE
    : Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis, Cancer 118: 3853-3859, 2012.
    OpenUrl
  5. ↵
    1. Dziggel L,
    2. Schild SE,
    3. Veninga T,
    4. Bajrovic A,
    5. Rades D
    : Clinical factors asssociated with treatment outcomes following whole-brain irradiation in patients with prostate cancer. In Vivo 31: 35-38, 2017.
    OpenUrlAbstract/FREE Full Text
    1. Sehmisch L,
    2. Schild SE,
    3. Rades D
    : Development of a survival score for patients with cerebral metastases from melanoma. Anticancer Res 37: 249-252, 2017.
    OpenUrlAbstract/FREE Full Text
    1. Rades D,
    2. Bartscht T,
    3. Schild SE
    : Predictors of survival in patients with brain metastases from gastric cancer. Neoplasma 64: 136-139, 2017.
    OpenUrl
    1. Rades D,
    2. Schild SE,
    3. Lohynska R,
    4. Veninga T,
    5. Stalpers LJ,
    6. Dunst J
    : Two radiation regimens and prognostic factors for brain metastases in non-small cell lung cancer patients. Cancer 110: 1077-1082, 2007.
    OpenUrlPubMed
    1. Rades D,
    2. Lohynska R,
    3. Veninga T,
    4. Stalpers LJ,
    5. Schild SE
    : Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer 110: 2587-2592, 2007.
    OpenUrlCrossRefPubMed
    1. Rades D,
    2. Fischer D,
    3. Veninga T,
    4. Stalpers LJ,
    5. Schild SE
    : Prognostic factors for survival and intracerebral control after irradiation for brain metastases from gynecological cancer. Gynecol Oncol 114: 506-508, 2009.
    OpenUrlPubMed
    1. Rades D,
    2. Dziggel L,
    3. Bartscht T,
    4. Gliemroth J
    : Predicting overall survival in patients with brain metastases from esophageal cancer. Anticancer Res 34: 6763-6765, 2014.
    OpenUrlAbstract/FREE Full Text
    1. Rades D,
    2. Dziggel L,
    3. Hakim SG,
    4. Rudat V,
    5. Janssen S,
    6. Trang NT,
    7. Khoa MT,
    8. Bartscht T
    : Predicting survival after irradiation for brain metastases from head and neck cancer. In Vivo 29: 525-528, 2015.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Rades D,
    2. Dziggel L,
    3. Veninga T,
    4. Bajrovic A,
    5. Schild SE
    : Overall survival after whole-brain radiation therapy for intracerebral metastases from testicular cancer. Anticancer Res 36: 4817-4819, 2016.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Kaplan EL,
    2. Meier P
    : Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
    OpenUrlCrossRef
  8. ↵
    1. Damaskos C,
    2. Garmpis N,
    3. Valsami S,
    4. Spartalis E,
    5. Antoniou EA,
    6. Tomos P,
    7. Karamaroudis S,
    8. Zoumpou T,
    9. Pergialiotis V,
    10. Stergios K,
    11. Michaelides C,
    12. Kontzoglou K,
    13. Perrea D,
    14. Nikiteas N,
    15. Dimitroulis D
    : Histone deacetylase inhibitors: A novel therapeutic weapon against medullary thyroid cancer? Anticancer Res 36: 5019-5024, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Käsmann L,
    2. Bolm L,
    3. Janssen S,
    4. Rades D
    : Prognostic factors for survival in patients treated with multimodal therapy for anaplastic thyroid cancer. Anticancer Res 36: 4697-4700, 2016.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Megwalu UC,
    2. Green RW
    : Total thyroidectomy versus lobectomy for the treatment of follicular thyroid microcarcinoma. Anticancer Res 36: 2899-2902, 2016.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Rades D,
    2. Janssen S,
    3. Käsmann L,
    4. Bolm L,
    5. Schild SE
    : Outcomes after irradiation of epidural spinal cord compression due to metastatic thyroid cancer. Anticancer Res 36: 2035-2039, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Do SI,
    2. Kim HS,
    3. Kim K,
    4. Lee H,
    5. Do IG,
    6. Kim DH,
    7. Chae SW,
    8. Sohn JH
    : Predictive value of sphingosine kinase 1 expression in papillary thyroid carcinoma. Anticancer Res 37: 5399-5405, 2017.
    OpenUrlAbstract/FREE Full Text
    1. Wojtczak B,
    2. Pula B,
    3. Gomulkiewicz A,
    4. Olbromski M,
    5. Podhorska-Okolow M,
    6. Domoslawski P,
    7. Bolanowski M,
    8. Daroszewski J,
    9. Dziegiel P
    : Metallothionein isoform expression in benign and malignant thyroid lesions. Anticancer Res 37: 5179-5185, 2017.
    OpenUrlAbstract/FREE Full Text
    1. Karagiannis AK,
    2. Girio-Fragkoulakis C,
    3. Nakouti T
    : Procalcitonin: A new biomarker for medullary thyroid cancer? A systematic review. Anticancer Res 36: 3803-3810, 2016.
    OpenUrlAbstract/FREE Full Text
    1. Londero SC,
    2. Jespersen ML,
    3. Krogdahl A,
    4. Bastholt L,
    5. Overgaard J,
    6. Schytte S,
    7. Godballe C,
    8. Alsner J,
    9. study from The Danish Thyroid Cancer Group-DATHYRCA (part of the DAHANCA organization)
    : Gene-expression classifier in papillary thyroid carcinoma: Validation and application of a classifier for prognostication. Anticancer Res 36: 749-756, 2016.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Masudo K,
    2. Suganuma N,
    3. Nakayama H,
    4. Oshima T,
    5. Rino Y,
    6. Iwasaki H,
    7. Matsuzu K,
    8. Sugino K,
    9. Ito K,
    10. Kondo T,
    11. Nakamura Y,
    12. Yoshihara M,
    13. Masuda M,
    14. Miyagi Y
    : EZH2 overexpression as a useful prognostic marker for aggressive behaviour in thyroid cancer. In Vivo 32: 25-31, 2018.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Rades D,
    2. Gerdan L,
    3. Segedin B,
    4. Nagy V,
    5. Khoa MT,
    6. Trang NT,
    7. Schild SE
    : Brain metastasis. Prognostic value of the number of involved extracranial organs. Strahlenther Onkol 189: 996-1000, 2013.
    OpenUrlPubMed
    1. Gerdan L,
    2. Segedin B,
    3. Nagy V,
    4. Khoa MT,
    5. Trang NT,
    6. Schild SE,
    7. Rades D
    : The number of involved extracranial organs: a new predictor of survival in breast cancer patients with brain metastasis. Clin Neurol Neurosurg 115: 2108-2110, 2013.
    OpenUrlPubMed
    1. Gerdan L,
    2. Šegedin B,
    3. Veninga T,
    4. Schild SE,
    5. Rades D
    : Number of involved extracranial organs predicts survival in patients with brain metastasis from small cell lung cancer. Anticancer Res 33: 3887-3889, 2013.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Gerdan L,
    2. Segedin B,
    3. Nagy V,
    4. Khoa MT,
    5. Trang NT,
    6. Schild SE,
    7. Rades D
    : Brain metastasis from non-small cell lung cancer (NSCLC): prognostic importance of the number of involved extracranial organs. Strahlenther Onkol 190: 64-67, 2014.
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 38 (4)
Anticancer Research
Vol. 38, Issue 4
April 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
18 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer
LIESA DZIGGEL, NIKLAS GEBAUER, TOBIAS BARTSCHT, STEVEN E. SCHILD, DIRK RADES
Anticancer Research Apr 2018, 38 (4) 2391-2394;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer
LIESA DZIGGEL, NIKLAS GEBAUER, TOBIAS BARTSCHT, STEVEN E. SCHILD, DIRK RADES
Anticancer Research Apr 2018, 38 (4) 2391-2394;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The Results of Whole-brain Radiotherapy for Elderly Patients With Brain Metastases from Urinary Bladder Cancer
  • Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer
  • Prognostic Role of Pre-Treatment Symptoms for Survival of Patients Irradiated for Brain Metastases
  • Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer
  • Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses
  • Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM
  • Google Scholar

More in this TOC Section

  • Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis
  • Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy
  • Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib
Show more Clinical Studies

Similar Articles

Keywords

  • Thyroid cancer
  • metastatic lesions to the brain
  • whole-brain radiotherapy alone
  • survival
  • predictive factors
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire